Key findings

  • 0.46 and 0.35approximate relative risks of severe mucositis and severe pain in a recent meta-analysis of about thirty trials
  • Level I / Highevidence for preventing oral mucositis, against Level IV / Very Low for treating it once established
  • Level III / Lowevidence for lymphedema-associated pain, with no proven superiority over placebo
  • 600 to 1100 nanometersthe red and near-infrared range in which photobiomodulation applies low power densities

Abstract

Background
Pain management in cancer patients represents a major clinical challenge due to its multimorphic nature. Photobiomodulation, defined as the therapeutic use of non-ionizing and athermal light radiation within the red and near-infrared spectrum, emerges as a promising non-pharmacological option to attenuate these symptoms and reduce reliance on systemic analgesics.1–6
Objective
This narrative review aims to critically evaluate the clinical efficacy of photobiomodulation in managing pain related to anticancer treatments, while providing clear guidance regarding dosimetric parameters, oncological safety, and current limitations in the literature.
Method
A narrative review of the literature was conducted. The sources consulted primarily included the PubMed and PubMed Central databases for publications extending up to 2026. The selection criteria focused on randomized controlled trials, systematic reviews, meta-analyses, and international consensus guidelines addressing painful complications in oncology.
Results
The strongest evidence supports the preventive efficacy of photobiomodulation for oral mucositis induced by radiotherapy or chimiotherapy, as well as for acute radiodermatitis.7–15 Results appear promising but remain insufficient for pain related to lymphedema and for chemotherapy-induced peripheral neuropathy.16–24 Pronounced protocol heterogeneity (variations in wavelengths, power, irradiance, and treatment frequencies) accounts for the divergence of certain clinical outcomes.
Limitations
The main weaknesses of the current literature reside in the variable methodological quality of studies, small sample sizes for secondary indications, a high risk of blinding bias, and a lack of rigorous standardization of parameters across equipment manufacturers.16–18
Conclusion
Photobiomodulation constitutes a useful tool in the multimodal analgesic strategy in oncology, provided it is delivered within validated therapeutic windows. The clinical message calls for caution: efficacy must not be overstated for curative indications or chronic sequelae, and direct irradiation of active, non-resected tumor sites must be strictly proscribed.

Introduction and Analgesic Mechanisms

Photobiomodulation attracts growing interest but also elicits a certain degree of mistrust. Presented at times empirically or confused with surgical lasers that exert thermal and ablative effects, this technique has historically suffered from a lack of clarity. It is, however, not new: first described in the late 1960s under the name of low-level laser therapy, it has since been reclassified under the term photobiomodulation to include non-coherent sources such as light-emitting diodes. It is defined by the application of low power densities in the red and near-infrared spectrum (600 to 1100 nanometers), triggering photochemical rather than thermal effects. For the pain physician, the stakes are concrete: having a non-invasive, low-iatrogenic approach that can potentially reduce medication load, particularly opioids.

The biological effect rests on the absorption of photons by intracellular chromophores, foremost among them mitochondrial cytochrome c oxidase. This absorption relieves the competitive inhibition exerted by nitric oxide on this enzyme. Nitric oxide is photodissociated, the respiratory chain is reactivated, the mitochondrial membrane potential increases, and adenosine triphosphate synthesis is stimulated. At therapeutic doses, the modulation of reactive oxygen species acts as a second messenger, activating transcription factors such as nuclear factor kappa B or nuclear factor erythroid 2. At excessive doses, this production induces deleterious oxidative stress, which explains the biphasic nature of the biological response according to the Arndt-Schulz law.

Several pathways contribute to analgesia:

  • The reduction of pro-inflammatory cytokine expression.
  • The improvement of local microcirculation, promoting the clearance of algogenic mediators.
  • Direct action on the nociceptive system, inducing reversible mitochondrial changes and a decrease in available adenosine triphosphate within dorsal root ganglion neurons. These mechanisms slow down or reversibly block conduction in small-caliber nerve fibers (C and AΔ fibers), disrupt axonal transport, and decrease the release of substance P.

Clinical Indications in Supportive Oncology Care

Oral mucositis

Radiation- and/or chemotherapy-induced oral mucositis represents the indication backed by the highest level of evidence. Randomized controlled trials and meta-analyses confirm that this technique reduces the incidence, severity, and associated pain, particularly when applied preventively.12–15 A recent meta-analysis compiling about thirty trials reports a significant reduction in the risk of severe mucositis (relative risk of approximately 0.46) and severe pain (relative risk of approximately 0.35). These data form the basis of clinical guidelines issued by the Multinational Association of Supportive Care in Cancer and the World Association for Light Therapy.

Critical Analysis of Evidence for Oral Mucositis

  • Typology and Methodology: Modern meta-analyses systematically aggregate between 15 and 30 randomized controlled trials, compiling data from 868 to over 1748 patients.12–15 Individual trials are predominantly monocentric with limited cohorts ranging from 30 to 100 patients, contrasting active irradiation against an acoustic and visual placebo (sham device) or against standard care (cryotherapy, sodium bicarbonate mouthwashes). Primary study endpoints rely on the grading scales of the World Health Organization or the National Cancer Institute. Secondary endpoints include subjective pain scores on the visual analog scale, total consumption of opioid analgesics, reliance on parenteral nutrition, and salivary flow rate. Follow-up is generally synchronized with oncotherapy regimens (2 to 7 weeks), with checkpoints extended to 30 to 90 days post-treatment. Preclinical data confirm the downregulation of pro-inflammatory cytokines (tumor necrosis factor alpha, interleukine 6) in cellular and animal models.
  • Strength of Evidence: The level of evidence is graded as Level I (strong recommendation) for the prevention of mucositis during hematopoietic stem cell transplantation conditioning regimens. It is graded as Level II (strong recommendation) for exclusive head and neck radiotherapy and combined chemoradiotherapy. Conversely, clinical data are deemed insufficient (Level III) for conventional chemotherapy of solid tumors, and very weak (Level IV) for pure curative utilization on pre-existing necrotic or ulcerated tissue.
  • Heterogeneity and Contradictory Results: Protocols vary significantly between the use of the visible red spectrum (632 to 685 nanometers) for superficial epithelial lesions and the near-infrared spectrum (780 to 830 nanometers) for the deeper transcutaneous route. Power outputs fluctuate from 20 to 100 milliwatts, and documented fluences range wildly from 1 J/cm² to over 100 J/cm², illustrating the therapeutic risk associated with the biphasic dose-response curve. Analyses reveal negative or conflicting results: therapeutic failure when initiated late on established grade 3 or 4 ulcers, absence of protective effect on deep salivary gland parenchyma (persistence of xerostomia), and a frequent paradox where lower reported pain scores do not consistently translate into a reduction in actual opioid consumption or shortened hospital stays. Furthermore, in vitro models show that direct exposure of squamous cell carcinoma lines can upregulate angiogenic factors, which mandates strictly excluding the illumination of active, non-resected tumor sites.

Radiodermatite

Acute radiodermatitis is the second best-documented indication. Randomized controlled trials support a preventive effect on the severity of radiation-induced skin reactions and associated local discomfort.7,9–11 International bodies attribute a high level of evidence to this indication.

Critical Analysis of Evidence for Radiodermatitis

  • Typology and Methodology: Meta-analyses compile cumulative data spanning 500 to 1000 patients. Individual trials (40 to 150 patients) frequently leverage an intra-patient control design (the irradiated skin field is split into two symmetrical halves, one side receiving active irradiation and the contralateral side receiving a sham intervention), thereby eliminating confounding variables such as skin phototype or natural elasticity. Primary endpoints evaluate severity according to the Radiation Therapy Oncology Group grades. Monitoring spans the 5 to 7 weeks of radiation therapy, extended up to 60 days post-radiation to capture the delayed acute inflammatory peak.
  • Strength of Evidence: The level of evidence is classified as Level II (high level of evidence) for the prevention of acute radiodermatitis in breast and head and neck cancers. Conversely, efficacy is judged insufficient (Level IV) for the curative treatment of chronic radiation damage (late fibrosis, telangiectasia).
  • Heterogeneity and Contradictory Results: Treating large anatomical regions requires large-field light-emitting diode panels or multi-diode cluster probes rather than narrow laser pens. Protocols frequently combine red (630 to 660 nanometers) and near-infrared (800 to 850 nanometers) wavelengths with fluences of 2 to 6 J/cm². Contradictions in the literature concern a complete absence of effect on chronic post-radiation fibrosis. Additionally, if the irradiance delivered by the panels is too high, a paradoxical surface skin heating can manifest, which directly violates fundamental radioprotection principles and can exacerbate skin injury deleteriously.

Lymphedema and breast-related pain sequelae

In upper-limb lymphedema following breast cancer treatment, the structural effect on volume reduction is better established than the specific analgesic effect.19–23 Systematic reviews report a volumetric benefit on fluid accumulation but inconsistent results regarding pain intensity, with certain high-quality trials showing no analgesic superiority over a sham treatment. Persistent chronic pain sequelae directly following breast surgery are currently supported only by observational cohort studies.

Critical Analysis of Evidence for Lymphedema and Breast-Related Pain

  • Typology and Methodology: Systematic overviews aggregate between 5 and 15 randomized controlled trials, representing a modest total cohort of 200 to 500 patients.19–21 Active irradiation is contrasted against a sham device or evaluated as an adjunct therapy alongside standard physical care, such as complete congestive therapy (including manual lymphatic drainage and compression bandaging). Endpoints calculate upper-limb volume reduction via water displacement or perometry, and pain via the visual analog scale or the McGill Pain Questionnaire. Follow-up ranges from 4 weeks to 12 months.
  • Strength of Evidence: The level of evidence is considered Level II (promising evidence) for lymphedema volume reduction as an adjunct to physical therapy.19–21 It drops to Level III (insufficient evidence) for lymphedema-associated pain relief, and to Level IV (weak evidence) for managing post-mastectomy pain syndrome due to the lack of large-scale controlled trials.
  • Heterogeneity and Contradictory Results: The need to reach deep lymphatic pathways and dense scarred tissue dictates the exclusive use of near-infrared wavelengths (780 to 904 nanometers). Applied fluences range from 1.5 to 10 J/cm² per point over lymphatic chains and fibrotic cords. The main conflict in the literature lies in the disconnect between objective tissue decongestion and subjective pain relief: the landmark clinical trial by Storz and colleagues demonstrates that under strict double-blind conditions, the specific analgesic benefit vanishes, highlighting a prominent placebo component or a statistical distortion overshadowed by the effects of concurrent manual drainage and compression.

Chemotherapy-induced peripheral neuropathy

Neuropathic pain induced by cytotoxic agents (taxanes, platinums, vinca alkaloids) represents an emerging and promising indication.16–18 Pilot randomized controlled trials, such as the NEUROLASER prevention trial or the sham-controlled trial by Argenta and colleagues, suggest efficacy regarding the intensity of painful symptoms and quality of life, though these findings await larger scale confirmation.16–17 The World Association for lIght Therapy includes this indication in its curative consensus frameworks.

Critical Analysis of Evidence for Chemotherapy-Induced Peripheral Neuropathy

  • Typology and Methodology: The current literature relies on a limited number of studies (5 to 12 trials, representing 150 to 450 total patients), with small individual cohorts (30 to 60 patients). Comparators combine sham applications or evaluation alongside standard pharmaceutical interventions such as duloxetine or gabapentinoids. Evaluation criteria track changes in pain scores, the total neuropathy score, and specific quality of life modules from the European Organisation for Research and Treatment of Cancer. Tracking is synchronized with chemotherapy cycles or spans 6 to 12 weeks post-treatment. Preclinical data show accelerated axonal regeneration and restoration of mitochondrial potential in dorsal root ganglion neuronal cultures.
  • Strength of Evidence: The level of evidence is graded as Level II (promising evidence) for the curative treatment of established sensory deficits. It sits at Level III (promitteur but insufficient) for prophylactic prevention started concurrently with chemotherapy, mandating confirmation by large-scale, multi-center trials.
  • Heterogeneity and Contradictory Results: The diffuse anatomical nature of the nerve deficits (stocking-and-glove distribution) requires large light-emitting diode panels or boots operating in the deep infrared spectrum (810 to 980 nanometers) with fluences of 4 to 10 J/cm². A major recurring paradox appears in the literature: while patients frequently describe a significant subjective reduction in pain and numbness, subsequent electromyography and objective nerve conduction studies do not consistently demonstrate a correlated restoration of nerve action potential amplitudes or conduction velocities. Furthermore, efficacy varies depending on the cytostatic drug used, showing weaker results for oxaliplatin-induced neuropathy, where acute cold hypersensitivity complicates the implementation of physical delivery protocols.

Therapeutic Parameters and Protocol Heterogeneity

Clinical efficacy strictly depends on an intricate set of interdependent physical variables: wavelength, power, irradiance (power density in milliwatts per square centimeter), fluence (energy density in Joules per square centimeter), exposure duration, treatment frequency, emission mode (continuous or pulsed), and treated surface area. This parametric complexity accounts for the apparent inconsistency across the literature: a notable proportion of negative trials prove, upon analysis, to be underdosed or fall outside the appropriate therapeutic window.

Delivery modalities must be tailored directly to the specific region treated:

  • Transcutaneous Route: The most common approach. The probe is applied in contact with the skin, point-by-point or via scanning. The achievable depth depends on the wavelength, near-infrared (800 to 1100 nanometers) penetrating much deeper than visible red (630 to 690 nanometers).
  • Endocavitary Route: Specialized probes are deployed in direct contact with mucosal surfaces (intraoral applicators for mucositis, or intravaginal and endorectal probes for pelvi-perineal sequelae).
  • Transcranial Route: Still exploratory, this route targets deep cerebral matrices through the scalp and bone, which dictates wavelengths and power levels optimized to cross dense cortical barriers.

In clinical practice, device selection is driven by the surface area and depth of the target lesion: a coherent laser is preferred for focal, deep structures, whereas light-emitting diode arrays are utilized for wide surfaces. Relying on validated dosimetric guidelines from the World Association for photobiomoduLation Therapy and the Association Francophone des Soins Oncologiques de Support is essential to structure clinical protocols.

Levels of Evidence: A Hierarchical Synthesis

The clinical body of evidence in pain medicine is profoundly heterogeneous. Table 1 synthesizes the levels of evidence for each indication across the Grading of Recommendations Assessment, Development and Evaluation criteria.

Table 1. Synthesis of Clinical Indications, Levels of Evidence, and Parametric Orientations

Clinical IndicationLevel of Evidence (GRADE)Clinical RecommendationPreferred Optical SpectrumGeneral Dosimetric Orientation
Oral Mucositis (Prevention)Level I / HighStrong recommendation; validated standard of careVisible red (630–660 nm) intra-orally; near-infrared transcutaneously1 to 4 J/cm² per spot; daily application or 3 times per week
Acute Radiodermatitis (Prevention)Level II / ModerateHigh recommendation; validated supportive careCombined red (630–660 nm) and near-infrared (800–850 nm)2 to 6 J/cm²; large-field panel application, 3 to 5 times per week
Peripheral Neuropathy (Curative)Level II / ModeratePromising supportive option; confirmation requiredDeep near-infrared (810–980 nm)4 to 10 J/cm²; extended limb extremity application, long sessions
Lymphedema (Fluid Volume)Level II / ModerateValid adjunct option within physical therapyNear-infrared (780–904 nm)6 to 10 J/cm² per point along lymphatic chains and scars
Lymphedema-Associated PainLevel III / LowInsufficient evidence; no proven superiority over placeboNear-infrared (780–904 nm)Variable parameters; specific analgesic efficacy not demonstrated
Oral Mucositis (Curative Treatment)Level IV / Very LowContradictory data; efficacy not establishedRed or near-infraredVariable parameters; late initiation ineffective on established ulcers
Post-Mastectomy Pain SyndromeLevel IV / Very LowPreliminary data; restricted to observational cohortsNear-infraredInsufficient data to formalize a standardized clinical protocol
Chronic Radiodermatitis (Fibrose)Level IV / Very LowAbsence of demonstrated efficacyNear-infraredIneffective on late tissue fibrosis and chronic skin atrophy

A cross-cutting reading reveals that efficacy is validated where standardized, rigorous protocols coexist (acute supportive care). Elsewhere, clinical demonstration must still be consolidated through high-power trials exempt from methodological biases.

Tolerability, Safety, and the Oncological Question

Photobiomodulation stands out for its excellent clinical tolerability profile. As a non-invasive, painless, and athermal modality, it exposes patients to no risk of burns or structural tissue damage when validated parameters are strictly observed. Documented adverse effects (transient erythema, localized warmth) remain rare, mild, and self-limiting.

In routine medical practice, implementation mandates compliance with fundamental precautions:

  • Ocular Protection: The mandatory use of certified protective eyewear, calibrated to the exact emitted wavelength, is indispensable for both the operator and the patient to eliminate retinal hazards from direct or scattered beams.
  • Absolute Local Contraindications: Direct irradiation over the thyroid gland, the pregnant uterus, or actively infected acute bacterial lesions remains strictly proscribed.
  • Photosensitization: Particular attention should be paid to patients concurrently taking highly photosensitizing medications, although the chosen spectral bands are located outside the ultraviolet range.

The most intensely debated issue surrounding this modality is its oncological safety. While certain experimental in vitro data on isolated cell lines have raised questions regarding potential proliferation or angiogenesis, large systematic reviews and clinical follow-up data report no deleterious effects on tumor growth, local recurrence, or overall patient survival. This safety consensus holds true even when treating the oral mucosa directly within the primary irradiated field for head and neck cancers. Data even suggest an indirect overall survival benefit, likely mediated by a significant reduction in severe treatment toxicities that would otherwise force life-threatening interruptions in chemotherapy or radiotherapy cycles. Safety is thus established within a formal medical setting but mandates avoiding direct application over an active, non-resected tumor mass.

Place in the Analgesic Strategy and Practical Aspects

Photobiomodulation is not intended to replace conventional analgesics but to be integrated within a multimodal care strategy. Its combination with physical exercise and masso-kinersithérapie illustrates a logic of reciprocal potentiation. Its value is twofold: offering a non-pharmacological option for polymedicated, frail patients or those in therapeutic impasse, and contributing to a strategy of sparing systemic analgesics, particularly opioids.

In France, this technique is delivered by pain physicians, physiotherapists, dental surgeons, and gynecologists, both within structures for the study and treatment of pain and in supportive oncology care departments. A major hurdle to its widespread diffusion remains the absence of specific coding and reimbursement within private practice, currently restricting financial coverage to clinical pathways completed in a hospital setting. The development of reference frameworks by the Association Francophone des Soins Oncologiques de Support contributes to harmonizing these practices nationally.

Limitations, Controversies, and Perspectives

The limitations of the current literature are clearly identified: heterogeneity of the included populations, technical diversity of hardware (lasers versus light-emitting diodes), incomplete descriptions of physical parameters in publications, technical difficulties in maintaining a true double-blind setup due to device characteristics, and modest sample sizes.16–18 These shortcomings limit the statistical power of meta-analyses and call for cautious clinical interpretation.

Future prospects of development rely on several scientific axes:

  • Methodological Standardization: The systematic adoption of strict editorial grids detailing all physical metrics (wavelength, power, irradiance, fluence, emission mode, surface) is an absolute priority to guarantee protocol replication.
  • Personalized Dosimetry and Biomarkers: Treatment optimization could rely on monitoring mitochondrial biomarkers (cytochrome c oxidase activity, adenosine triphosphate levels), inflammatory markers (interleukine 6, C-reactive protein), or non-invasive optical measurements via near-infrared spectroscopy to reflect tissue redox states in real-time.
  • Technological Innovations: The development of automated devices equipped with integrated power meters will allow clinicians to control real-time fluence delivered to the skin, adapting dynamically to individual variations in skin reflectance and systematically preventing the inhibitory biphasic curve.
  • Health-Economic Evaluations: Conducting rigorous cost-effectiveness studies measuring the precise impact of the technique on reducing drug consumption, lowering hospital lengths of stay, and improving quality of life scores will be decisive in justifying its formal inclusion in official reimbursement nomenclatures.

Conclusion

Photobiomodulation has successfully moved beyond the realm of marginal practices to establish itself as a therapeutic tool in its own right, backed by identified biological mechanisms and an excellent clinical safety profile. Its level of scientific evidence, however, remains contrasted: high and validated in supportive oncology care for the prevention of acute mucositis and radiodermatitis, it remains moderate or preliminary for managing chronic pain, neuropathies, or lymphedema sequelae.7–24 Far from both unfounded promises and dogmatic rejections, this technique must be considered for what it truly is: a credible, complementary analgesic tool for well-defined indications, demanding absolute rigor in the delivery of physical parameters.

Declarations

Declaration of Interests
The author declares no conflicts of interest in relation to this article.

References

  1. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg. 2015;33(4):183-184. doi:10.1089/pho.2015.9848
  2. Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516-533. doi:10.1007/s10439-011-0454-7
  3. de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417. doi:10.1109/JSTQE.2016.2561201
  4. Cheng K, Martin LF, Slepian MJ, Patwardhan AM, Ibrahim MM. Mechanisms and pathways of pain photobiomodulation: a narrative review. J Pain. 2021;22(7):763-777. doi:10.1016/j.jpain.2021.02.005
  5. Zhang WW, Wang XY, Chu YX, Wang YQ. Light-emitting diode phototherapy: pain relief and underlying mechanisms. Lasers Med Sci. 2022;37(5):2343-2352. doi:10.1007/s10103-022-03540-0
  6. Cronshaw M, Parker S, Arany P. Feeling the heat: evolutionary and microbial basis for the analgesic mechanisms of photobiomodulation therapy. Photobiomodul Photomed Laser Surg. 2019;37(9):517-526. doi:10.1089/photob.2019.4684
  7. Robijns J, Nair RG, Lodewijckx J, et al. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. Front Oncol. 2022;12:927685. doi:10.3389/fonc.2022.927685
  8. Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines (MASCC/ISOO). Support Care Cancer. 2019;27(10):3969-3983. doi:10.1007/s00520-019-04890-2
  9. Lairedj K, Klausner G, Robijns J, Arany PR, Bensadoun RJ. Photobiomodulation dans la prévention et la prise en charge des effets secondaires des traitements anticancéreux : bases, bilan et perspectives. Bull Cancer. 2024;111(3):314-326. doi:10.1016/j.bulcan.2023.08.011
  10. Klausner G, Bensadoun RJ, Champion A, et al. État de l’art de la photobiomodulation dans la prise en charge des effets secondaires de la radiothérapie : indications et niveaux de preuve. Cancer Radiother. 2021;25(6-7):584-592. doi:10.1016/j.canrad.2021.06.025
  11. Association Francophone des Soins Oncologiques de Support. Référentiel AFSOS 2026 : « Photobiomodulation en soins oncologiques de support ». AFSOS; 2026 (on line in October 2026). https://www.afsos.org/
  12. Pedroso MNM, Rech A, Casagrande N, et al. Effects of photobiomodulation on oral mucositis, oral pain, xerostomia, salivary flow rate, and quality of life in patients with head and neck cancer: a systematic review and meta-analysis. Support Care Cancer. 2026;34:364. doi:10.1007/s00520-026-10575-4
  13. Shen B, Zhou Y, Wu D, Liu J. Efficacy of photobiomodulation therapy in the management of oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis of randomized controlled trials. Head Neck. 2024;46(4):936-950. doi:10.1002/hed.27655
  14. Al-Rudayni AHM, Gopinath D, Maharajan MK, Veettil SK, Menon RK. Efficacy of photobiomodulation in the treatment of cancer chemotherapy-induced oral mucositis: a meta-analysis with trial sequential analysis. Int J Environ Res Public Health. 2021;18(14):7418. doi:10.3390/ijerph18147418
  15. Sánchez-Martos R, Lamdaoui W, Arias-Herrera S. Therapeutic outcomes of photobiomodulation in cancer treatment-induced oral mucositis: a systematic review. J Clin Exp Dent. 2023;15(9):e749-e759. doi:10.4317/jced.60710
  16. Argenta PA, Ballman KV, Geller MA, et al. The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: a randomized, sham-controlled clinical trial. Gynecol Oncol. 2017;144(1):159-166. doi:10.1016/j.ygyno.2016.11.013
  17. Lodewijckx J, Robijns J, Claes M, et al. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER). Support Care Cancer. 2022;30(6):5509-5517. doi:10.1007/s00520-022-06975-x
  18. Claes M, Lodewijckx J, Robijns J, Hermans S, Peeters P, Mebis J. Evaluating the efficacy of photobiomodulation therapy in the management of chemotherapy-induced peripheral neuropathy: a pilot trial (NEUROLIGHT trial). Lasers Med Sci. 2026;41(1):57. doi:10.1007/s10103-026-04852-1
  19. Baxter GD, Liu L, Petrich S, et al. Low level laser therapy (photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review. BMC Cancer. 2017;17(1):833. doi:10.1186/s12885-017-3852-x
  20. Mahmood D, Ahmad A, Sharif F, Arslan SA. Clinical application of low-level laser therapy (photobiomodulation therapy) in the management of breast cancer-related lymphedema: a systematic review. BMC Cancer. 2022;22(1):937. doi:10.1186/s12885-022-10021-8
  21. Chiu ST, Lai UH, Huang YC, Leong CP, Chen PC. Effect of various photobiomodulation regimens on breast cancer-related lymphedema: a systematic review and meta-analysis. Lasers Med Sci. 2024;39(1):11. doi:10.1007/s10103-023-03959-z
  22. Storz MA, Gronwald B, Gottschling S, Schöpe J, Mavrova R, Baum S. Photobiomodulation therapy in breast cancer-related lymphedema: a randomized placebo-controlled trial. Photodermatol Photoimmunol Photomed. 2017;33(1):32-40. doi:10.1111/phpp.12284
  23. Smoot B, Chiavola-Larson L, Lee J, Manibusan H, Allen DD. Effect of low-level laser therapy on pain and swelling in women with breast cancer-related lymphedema: a systematic review and meta-analysis. J Cancer Surviv. 2015;9(2):287-304. doi:10.1007/s11764-014-0411-1
  24. Ahmed Omar MT, Abd-El-Gayed Ebid A, El Morsy AM. Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study. J Surg Res. 2011;165(1):82-90. doi:10.1016/j.jss.2010.03.050

Article information

Authors

How to cite

Bensadoun, R.-J., Lairedj, K., 2026. Photobiomodulation for Pain Management: Mechanisms, Clinical Evidence, Treatment Parameters, and Practical Considerations for Clinicians — A Narrative Review. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0675

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
96

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.